Combination of CPT-11 and Cisplatin for Lung Cancer
Author Information
Author(s): N Masuda, M Fukuoka, A Fujita, Y Kurita, S Tsuchiya, K Nagao, S Negoro, H Nishikawa, N Katakami, K Nakagawa, H Niitani
Primary Institution: Osaka Prefectural Habikino Hospital
Hypothesis
The study aims to confirm the activity and toxicities of CPT-11 and cisplatin combination for previously untreated non-small-cell lung cancer (NSCLC).
Conclusion
The combination of CPT-11 and cisplatin is effective against non-small-cell lung cancer with acceptable toxicities.
Supporting Evidence
- Thirty-three patients (52%) achieved an objective response, with one complete response (2%) and 32 partial responses (50%).
- The median duration of response was 19 weeks and the overall median survival time was 44 weeks.
- The 1-year survival rate was 33%.
Takeaway
Doctors tested a new medicine called CPT-11 with another medicine called cisplatin to help people with a type of lung cancer, and it worked pretty well.
Methodology
Seventy patients with stage IIIB or IV NSCLC received CPT-11 and cisplatin in a multi-institutional phase II study, with assessments made of response, survival, and toxicities.
Limitations
The study had a small sample size and was limited to previously untreated patients.
Participant Demographics
The median age of participants was 61 years, with 51 males and 18 females.
Statistical Information
P-Value
0.178
Confidence Interval
95% confidence interval 39-64%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website